New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
15:03 EDTFRX, ARRYArray BioPharma hires new Chief Scientific Officer, VP of R&D
Array BioPharma (ARRY) announced the appointments of Nicholas Saccomano, Ph.D., as Chief Scientific Officer and Robert Winkler, M.D., as VP of Clinical Research and Development. Saccomano most recently served as Chief Technology Officer at SomaLogic and as Chief Scientific Officer at Bend Research. Winkler most recently served as VP of Global Clinical Development and Operations at Aptalis Pharma, which was recently acquired by Forest Labs (FRX).
News For ARRY;FRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2015
17:29 EDTARRYArray BioPharma files automatic mixed securities shelf
August 17, 2015
06:22 EDTARRYPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use